2009, Number 2
PDF size: 106.26 Kb.
Text ExtractionAkira Endo identified a cholesterol-lowering substance that antagonized HMGCoA reductase, decreasing cholesterol biosynthesis. These studies led to the development of statin, which was efficient to decrease cholesterol levels in blood in order to prevent atherosclerosis and cardiovascular disease.
Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Cholesterol Treatment Trialists’ (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 2005; 366(9493):1267-1278.
Shanes JG, Minadeo KN, Moret A, Groner M. Statin therapy in heart failure: prognostic effects and potential mechanisms. Am Heart J 2007;154:617-623.
Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, et al. Pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22 (PROVE IT-TIMI 22) investigators. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005;352(1):20-28.
Calabro P, Yeh ET. The pleiotropic effects of statins. Curr Opin Cardiol 2005;20(6):541-546.
Tobert JA. Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors. Nat Rev Drug Discov 2003;2(7):517-526.
Goldstein JL, Brown MS. The low-density lipoprotein pathway and its relation to atherosclerosis. Annu Rev Biochem 1977; 46: 897-930.
Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, et al. JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359(21):2195-207.